OvaScience Appoints Thomas Malley to Board of Directors

  OvaScience Appoints Thomas Malley to Board of Directors

Business Wire

CAMBRIDGE, Mass. -- October 31, 2012

OvaScience^SM, a life sciences company focused on the discovery, development
and commercialization of new treatments for infertility, announced the
appointment of Thomas Malley to its Board of Directors.

“Tom’s knowledge of the healthcare industry and his expertise in identifying
companies with breakthrough technologies will be invaluable to OvaScience as
we seek to develop and commercialize new treatments for infertility,” said
Michelle Dipp, M.D., Ph.D., Chief Executive Officer and Co-Founder of
OvaScience.

Since 2007, Mr. Malley has served as President of Mossrock Capital, a private
investment firm in Denver. Prior to Mossrock Capital, Mr. Malley served in
various roles at Janus Mutual Funds for 16 years. From 1999 to 2007, Mr.
Malley started and served as the Portfolio Manager of the Janus Global Life
Sciences Fund and served as Vice President of the Janus Healthcare team. Prior
to that, he served as an equity analyst for Janus from 1991 to 1998, covering
healthcare and biotechnology, telecommunications, gaming and lodging, and
housing stocks. Mr. Malley currently serves on the Board of Directors of
publicly traded biotechnology firms Synageva Biopharma Corp. and Puma
Biotechnology, Inc. Previously, he served on the Board of Cougar
Biotechnology, Inc. from 2007 to 2009, prior to the company’s acquisition by
Johnson and Johnson. Mr. Malley holds a B.S. in biology from Stanford
University.

“OvaScience is driving innovation in an area of healthcare where new
approaches are needed to improve the treatment of infertility,” said Mr.
Malley. “I look forward to working closely with management and the Board to
realize the value of OvaScience’s egg precursor cell platform to generate new
product opportunities.”

About OvaScience

OvaScience is a life sciences company focused on the discovery, development
and commercialization of new treatments for infertility. The Company’s
patented technology is based on the discovery of egg precursor cells
(EggPC^SM), which are found in the ovaries. By applying proprietary technology
to identify and purify EggPCs, AUGMENT^SM aims to improve egg quality and
increase the success of in vitro fertilization (IVF). OvaScience’s team of
scientists, physicians and advisers includes recognized leaders in the field
of reproductive medicine.

Contact:

OvaScience, Inc.
Theresa McNeely, 617-299-7356
Head of Corporate Communications
tmcneely@ovascience.com